Patients may self-inject Nemluvio after receiving training on SC injection technique. The Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab-ilto) for the treatment of adults with ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Nemluvio (nemolizumab-ilto) to treat adults with prurigo nodularis. The approval was supported ...

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...

NEW ORLEANS -- An investigational antibody targeting interleukin (IL)-31 in prurigo nodularis significantly reduced itch, skin lesions, and sleep disturbance in a phase III trial. More than half of ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi (SNY) announced Thursday that the European Commission has expanded the marketing authorization for Dupixent (dupilumab) ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly what ...

For patients with moderate-to-severe prurigo nodularis, nemolizumab improves symptoms, according to a study published in the Oct. 26 issue of the New England Journal of Medicine. Shawn G. Kwatra, M.D.

Aiming to offer an advantage over Dupixent (dupilumab, Regeneron Pharmaceuticals Inc.), dermatology-focused Galderma Holding SA won clearance from the U.S. FDA for Nemluvio (nemolizumab) as a ...